Organization
University of Bath, Centre for Therapeutic Innovation, Department of Life Sciences, Bath, United Kingdom
1 abstract
Abstract
BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIESOrg: Nuffield Orthopaedic Centre, Oxford, United Kingdom, Oxford University Hospitals NHS Trust, University of Oxford and Oxford Biomedical Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Oxford, United Kingdom, Copenhagen University Hospital, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States of America, Royal National Hospital of Rheumatic Diseases, Bath, United Kingdom,